Présentation

P7-3 Impact on immunogenicity: Dose, Schedule and Platform

Andrew Pollard

GVIRF 2023 Presentation

Auteurs

Langues

  • Anglais

Année de publication

2023

Type

Présentation

Catégories

  • Initiatives mondiales

GVIRF-2023

Cette ressource apparaît sur le Thème suivant:

Cette ressource est incluse dans le tableau suivant:

TitreAuteurAnnéeTypeLangue
P8 - Reflections and closing remarks: Progress and the path forwardNoni MacDonald, Dalhousie U.2023WebinarAnglais
GVIRF 2023 Welcome and Opening RemarksLee Hall2023WebinarAnglais
Keynote 1 - Vaccines in the Post-COVID Era: Can Policy and Practice Keep up with ScienceBarney Graham2023WebinarAnglais
P2 - Lessons from COVID-19 vaccines and future pandemic preparednessCharlie Weller2023WebinarAnglais
W8 - Select poster highlightsPeter Dull, Sinead Delany-Moretlwe2023WebinarAnglais
P5-3 Using mHealth Interventions to Improve Vaccination CoverageAbdul Momin Kazi2023PresentationAnglais
W7 - New vaccines on the horizonAlejandro Cravioto, Shahida Baqar2023WebinarAnglais
P6 - Vaccine technologies for equityPhilippe-Alexandre Gilbert2023WebinarAnglais
W5 - Vaccine development strategies at the intersection of market model, value drivers, and access policyJessica Martinez, Raman Rao2023WebinarAnglais
W4 - Mucosal immunity and vaccinesMelanie Saville2023WebinarAnglais
P3 - Current status of R&D for HIV, TB, Malaria, and Universal Influenza vaccines (and reports from Workshops 1-3)Annie Mo, Jerome Kim2023WebinarAnglais
W3 - Regional manufacturingMartin Friede2023WebinarAnglais
W2 - Novel vaccine platformsMax Silverman, Sue Ann Clemens2023WebinarAnglais
W1 - Immunological and Vaccine Considerations for Special Populations: women of reproductive age and pregnancy, people living with HIV, and older adultsCarolyn Deal, Ruth Karron2023WebinarAnglais
P6-3 A low footprint vaccine manufacturing platform for in-country, for-country productionMathias Garny2023PresentationAnglais
P5-4 Strengthening Routine Immunization: Use of Reaching Every District - Quality Improvement (RED-QI) approachMelkamu Ayalew2023PresentationAnglais
W8-9 Polyvalent strategy to the development of broadly protective vaccines against COVID-19 subvariantsChang-Yuil Kang2023PresentationAnglais
W8-8 The landscape of infectious disease exposure over the past two decades in the Kenyan coastTimothy Chege2023PresentationAnglais
W8-7 RV 460 Study: Comparative Adjuvant Study or HIV Env-C DNA and Protein Vaccines in KenyaJosphat Kiprop Kosgei2023PresentationAnglais
W8-6 Nucleoprotein Antigen Adjuvanted with Liposomal Cholesterol-linked TLR7/8 Agonist Showed Protective Immunity in Influenza Mouse ModelChul Kim2023PresentationAnglais
W8-4 Innovative DDS "DegradaBALL" for mRNA vaccine against next pandemics: "100 days mission"Dal-Hee Min2023PresentationAnglais
W8-5 Cross-neutralization of Influenza A by SARS-CoV-2 antibodiesMohammad Mamun Alam2023PresentationAnglais
W8-3 High prevalence of rotavirus infection among under five children despite a high rotavirus vaccination coverage in EthiopiaDebasu Damtie2023PresentationAnglais
W8-2 Changing the HPV Landscape with Indigenous Vaccine: CERVAVACHitt Sharma2023PresentationAnglais
W8-1 Workshop 8: Select Poster HighlightsPeter Dull2023PresentationAnglais
W7-4 Enteric Disease: Shigella and ETEC Vaccine DevelopmentMichelo Simuyandi2023PresentationAnglais
W7-3 2023: the year of RSVRuth Karron2023PresentationAnglais
W7-2 Dengue VaccinesAnnelies Wilder-Smith2023PresentationAnglais
W6-5 Protecting young infants through immunopreventionJessica Fleming2023PresentationAnglais
W6-4 Reaching adolescent girls with the HPV vaccineCathy Ndiaye2023PresentationAnglais
W6-3 Implementation research needs on vaccine delivery according to epidemiological contextHalidou Tinto2023PresentationAnglais
W6-1 What is implementation research and why is it important?Alexander Rowe2023PresentationAnglais
W5-5 Developing vaccines as global public good: RIGHT foundation’s approachHani Kim2023PresentationAnglais
W5-4 The Next Frontier in Defining Value: Health Economics in LMICsAlice Chen2023PresentationAnglais
W4-6 A translational Research Institute focused on vaccines and airway immunityPeter Andersen2023PresentationAnglais
W4-5 mRNA-lipid nanoparticle vaccines for intranasal deliveryDarin Edwards2023PresentationAnglais
W4-4 Adenovirus Vector Based Covid-19 Inhalation VaccineChunlin Xin2023PresentationAnglais
W4-3 A Mucosally-delivered Newcastle Disease Virus-vectored Booster Vaccine to Prevent SARS-CoV-2 Breakthrough Infection and TransmissionMichael Egan2023PresentationAnglais
W4-2 Mucosal Immunity: What’s special about it and can vaccines induce it?Peter Openshaw2023PresentationAnglais
W4-1 Mucosal Immunity: Opening RemarksMelanie Saville2023PresentationAnglais
W3-5 The case for globally distributed vaccine manufacturing - CEPI perspectiveMelanie Saville2023PresentationAnglais
W2-3 mRNA and adjuvants friends…or foes ?Nathalie Garcon2023PresentationAnglais
W3-4 Gavi’s Strategy to Support Regional ManufacturingMarta Tufet2023PresentationAnglais
W3-3 Biological E. LimitedMahima Datla2023PresentationAnglais
W3-2 An African Mission - Establish and SustainPatrick Tippoo2023PresentationAnglais
W2-5 New Developments in Viral Vector VaccinesJerry Sadoff2023PresentationAnglais
W2-4 Nanoparticle Vaccines: A success story for viral vaccine developmentHarry Kleanthous2023PresentationAnglais
W1-5 COVID 19 vaccine effectiveness in the elderly populationTarun Saluja2023PresentationAnglais
W1-4 TB Vaccine Roadmap for People Living with HIVMindy Miner2023PresentationAnglais
W1-3 Group B Streptococcus Vaccination in Pregnant WomenAnna Seale2023PresentationAnglais

Ajouté par: Angela Hwang

Ajouté le: 2023-04-02 02:14:48

Consultations: 1672

Fichier téléchargé

P7-3 Pollard.pdf

Cliquez pour télécharger

Signaler un problème

Ajouter une ressource